148760-75-2

Basic information

• Product Name: 1-Boc-1H-pyrrolo[3,2-c]pyridine
• Synonyms: 1-Boc-1H-pyrrolo[3,2-c]pyridine;1H-Pyrrolo[3,2-c]pyridine-1-carboxylic acid, 1,1-diMethylethyl ester;1H-Pyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester
• CAS NO: 148760-75-2
• Molecular Formula: C₁₂H₁₄N₂O₂
• Molecular Weight: 218
• Mol File: 148760-75-2.mol

Chemical Properties

• Boiling Point: 339.3±34.0 °C(Predicted)
• Appearance: /
• Density: 1.14±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 7.02±0.30(Predicted)
• CAS DataBase Reference: 1-Boc-1H-pyrrolo[3,2-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-1H-pyrrolo[3,2-c]pyridine(148760-75-2)
• EPA Substance Registry System: 1-Boc-1H-pyrrolo[3,2-c]pyridine(148760-75-2)

Safety Data

• Hazardous Substances Data: 148760-75-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-Boc-1H-pyrrolo[3,2-c]pyridine is used as a reagent in pharmaceutical research for the synthesis of targeted drug molecules. Its heterocyclic structure and Boc protecting group contribute to the development of bioactive compounds with potential therapeutic applications.
Used in Organic Synthesis:
1-Boc-1H-pyrrolo[3,2-c]pyridine is utilized as a reagent in various organic synthesis processes. Its unique structure allows for versatile chemical reactions, enabling the creation of a wide range of molecules with different properties and applications.

Upstream product

• 1678-53-1 4-nitro-3-methylpyridine 
• 271-29-4 6-azaindole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3005-27-4 3,4-dibromo-1-methyl-2,5-dihydropyrrole-2,5-dione 
• 877060-51-0 1-Boc-3-trimethylstannyl-5-azaindole 
• 211029-70-8 (3-Trimethylsilanylethynyl-pyridin-4-yl)-carbamic acid tert-butyl ester 
• 148760-46-7 3-(4-Morpholinovinylene)-4-nitropyridine 1-oxide 
• 148760-47-8 3-Dimethylaminovinylene-4-nitropyridine 
• 1074-98-2 3-methyl-4-nitropyridine N-oxide 
• 211029-67-3 (3-iodo-pyridin-4-yl)-carbamic acid tert-butyl ester 
• 123367-22-6 (E)-N,N-dimethyl-2-(4-nitro-1-oxidopyridin-3-yl)ethenamine 
• 211029-69-5 (3-Ethynyl-pyridin-4-yl)-carbamic acid tert-butyl ester 
• 271-34-1 5-azaindole 

Downstream Products

• 219834-81-8 tert-butyl 2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1147422-00-1 tert-butyl octahydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1373491-82-7 8-(2-chlorophenyl)-2,2-dimethyl-8-(1,4,6,7-tetrahydropyrrolo[3,2-c]pyridin-5-yl)-octanoic acid 
• 1373491-83-8 8-(2-chlorophenyl)-2,2 dimethyl-8-(1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-5-yl)-octanoic acid ethyl ester 
• 1373492-30-8 5-(1-(2-chlorophenyl)-7-ethoxycarbonyl-7-methyloctyl)-4,5,6,7-tetrahydropyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester 
• 271-34-1 5-azaindole 
• 848410-13-9 tert-butyl rac-(3aR,7aS)-octahydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 848410-13-9 tert-butyl (3aS,7aR)-2,3,3a,4,5,6,7,7a-octahydropyrrolo[3,2-c]pyridine-1-carboxylate 
• 1373273-47-2 (1-(tert-butoxycarbonyl)-1H-pyrrolo[3,2-c]pyridin-2-yl)boronic acid 

Relevant articles and documents

Transition metal catalyzed synthesis of 5-azaindoles

In an effort to develop synthetic procedures for the preparation of 2- substituted 5-azaindoles, the synthesis and cyclization reactions of acetylenic aminopyridines was explored. A novel method for the synthesis of 2-substituted 5-azaindoles via a transi

HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES

Provided herein are Heterocyclic compounds of formula (I): and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein W, X, Y, R1, R2, and RN are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound, and methods for treating or preventing animal and human filarial worm infections and diseases.

INDOLO-SUBSTITUTED-PIPERIDINE COMPOUNDS AS ESTROGEN RECEPTOR DEGRADING AGENT

Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer.

PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER

The present application relates to a compound of Formula I, or a salt, hydrate or solvate thereof, as defined herein. The present compounds are found to have pharmacological effects, particularly at MRCK. Further provided are pharmaceutical compositions comprising said compounds. The present invention also relates to the use of these compounds as therapeutic agents, in particular, for the treatment and/or prevention of proliferative diseases, such as cancer.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF

6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter-and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.